论文部分内容阅读
由于ATRA在APL的显著作用,人们注意到ATRA在其它血液病方面的潜在抗白血病作用,但目前为止ATRA在CML慢性期的作用无人报导。本文研究了ATRA间歇给药治疗Ph~+CML慢性期病人。 材料和方法:18例Ph~+CML慢性期病人男女各9例,中位年龄58岁,诊断到治疗时间平均为21个月,用α-IFN和/或Hu或Bus治疗的15例,未用的3例,当病人WBC>10×10~9/L,用Hu2g/d口服;WBC<10×10~9/L,停Hu,立即用ATRA80mg/m~2.d,tid.po。每隔1周连续7天,总共12疗程(1疗程=用药1周,间歇1周)。WBC>50×10~9/L和/或PLT<1500×10~9/L,停用ATRA。12疗程后WBC<10×10~9/L,PLT<500×10~9/L,Hb>11g/dl,脾触不清时进行细胞遗传学检查。ATRA剂量的
Due to the significant role of ATRA in APL, people have noticed the potential anti-leukemia effect of ATRA in other hematological diseases, but so far no role for ATRA in the chronic phase of CML has been reported. This article studied ATRA intermittent treatment of patients with chronic Ph+CML. Materials and Methods: Eighteen male and nine female patients with Ph+CML in chronic phase were included in the study. The median age was 58 years. The average time of treatment was 21 months. 15 patients treated with α-IFN and/or Hu or Bus, not In 3 cases, when the patient WBC> 10 × 10 ~ 9 / L, oral Hu2g / d; WBC <10 × 10 ~ 9 / L, Hu stopped, immediately with ATRA 80mg / m ~ 2.d, tid.po. Every 7 weeks for 7 days, a total of 12 courses (1 course = 1 week in medication, 1 week in interval). WBC>50×10~9/L and/or PLT<1500×10~9/L, disable ATRA. After 12 courses of WBC<10×10~9/L, PLT<500×10~9/L, Hb>11g/dl, cytogenetic examination was performed when the spleen was not clear. ATRA dose